Table 4 Sensitivity analyses for DMCs, DNMCs, ICs, and total costs of MS patients based on drug therapy lines studied in Iran in 2019
From: Economic burden of multiple sclerosis: a cross-sectional study in Iran
Disease Type | Number of Patients in Iran | DMC | DNMC | IC | COI |
|---|---|---|---|---|---|
A: One-way Sensitivity analysis ($ PPP) | |||||
 First line | 29,378–86,303 | 26,169,322-76,877,576 | 20,396,319-59,918,234 | 9,808,024-28,813,017 | 56,373,665 -165,608,827 |
 Second line | 12,590–36,987 | 36,609,931-107,548,937 | 9,428,969-27,699,466 | 5,352,819-15,724,967 | 51,391,719-150,973,370 |
 Total | 41,968–123,290 | 62,779,253-184,426,513 | 29,825,288-87,617,700 | 15,160,843-44,537,984 | 107,765,384-316,582,198 |
B: One-way Sensitivity analysis ($ PPP) | |||||
 First line | 51,230 | 31,397,122-64,437,117 | 24,470,856-50,222,164 | 11,767,356-24,150,446 | 67,635,334-138,809,726 |
 Second line | 21,956 | 43,923,433-90,145,186 | 11,312,577-23,217,091 | 6,422,142-13,180,326 | 61,658,152-126,542,604 |
 Total | 73,186 | 81,137,165-166,519,878 | 36,983,018-75,901,195 | 18,909,179-38,807,791 | 137,029,362-281,228,865 |
C: Two-way Sensitivity analysis ($ PPP) best-case scenario and worst-case scenario | |||||
 First line | 29,378–86,303 | 18,004,494- 108,551,138 | 14,032,667- 84,604,546 | 6,747,921- 40,683,980 | 38,785,082- 233,839,664 |
 Second line | 12,590–36,987 | 25,187,633- 151,859,099 | 6,487,130- 39,111,646 | 3,682,739- 22,203,654 | 35,357,502- 213,174,399 |
 Total | 41,968–123,290 | 46,527,627- 280,520,346 | 21,207,693- 127,863,590 | 10,843,357- 65,375,829 | 78,578,676- 473,759,765 |